Hypercoagulable State in Patients with Schizophrenia: Different Effects of Acute and Chronic Antipsychotic Medications

Overview

Journal Ther Adv Psychopharmacol

Specialty Psychiatry

Date 2023 Oct 2

PMID 37781686

Authors

Caiji Zheng

Haiyan Liu

Weifeng Tu

Lingyun Lin

Haiyun Xu

Affiliations

Soon will be listed here.

Abstract

Background: Previous studies reported higher incidences of venous thromboembolism and cardiovascular disease in schizophrenia patients and higher indicators of thrombosis, thrombocyte activation, and platelet dysfunction.

Objectives: To check if first-episode schizophrenia (FES) patients have a hypercoagulable state and determine whether acute and chronic antipsychotics have the same effect on blood coagulation or fibrinolysis-related biomarkers.

Design: Case-control study.

Methods: A total of 81 participants were grouped in FES, chronic schizophrenia (CS), and healthy controls (HCs). In addition to demographic data and clinical characteristics, immunological analyses were performed to measure plasma levels of D-dimer, plasminogen activator inhibitor-1 (PAI-1), soluble P selectin (sP-sel), tissue plasminogen activator (tPA), thrombotic precursor protein (TpP), and von Willebrand's disease factor (vWF).

Results: Compared to HC group, FES patients showed higher PAI-1 (28.61 ng/ml 15.69 ng/ml), sP-sel (2.78 ng/ml 1.18 ng/ml), and TpP (15.61 µg/ml 5.59 µg/ml) along with a higher PAI-1/tPA (3.12 2.00). Acute antipsychotic medication reduced higher PAI-1 (28.61 → 21.99), sP-sel (2.78 → 1.87), tPA (9.59 → 5.83), TpP (15.61 → 10.54), and vWF (383.18 → 291.08) in FES patients. However, plasma sP-sel and vWF in CS patients returned to the pre-treatment levels in FES patients, and PAI-1/tPA significantly decreased compared to FES patients.

Conclusion: These results suggest a hypercoagulable state in FES patients and demonstrate contrast effects of acute and chronic antipsychotics on coagulation or fibrinolysis in schizophrenia patients.

Citing Articles

COVID-19 and Antipsychotic Therapy: Unraveling the Thrombosis Risk.

Dho-Nagy E, Brassai A, Lechsner P, Ureche C, Ban E Int J Mol Sci. 2024; 25(2).

PMID: 38255892 PMC: 10815664. DOI: 10.3390/ijms25020818.

References

Carville D, Dimitrijevic N, Walsh M, Digirolamo T, Brill E, Drew N . Thrombus precursor protein (TpP): marker of thrombosis early in the pathogenesis of myocardial infarction. Clin Chem. 1996; 42(9):1537-41. View

Gravanis I, Tsirka S . Tissue-type plasminogen activator as a therapeutic target in stroke. Expert Opin Ther Targets. 2008; 12(2):159-70. PMC: 3824365. DOI: 10.1517/14728222.12.2.159. View

Szuster-Ciesielska A, Slotwinska M, Stachura A, Marmurowska-Michalowska H, Kandefer-Szerszen M . Neuroleptics modulate cytokine and reactive oxygen species production in blood leukocytes of healthy volunteers. Arch Immunol Ther Exp (Warsz). 2004; 52(1):59-67. View

Lally J, Spaducci G, Gardner-Sood P, Atakan Z, Greenwood K, Di Forti M . Tobacco smoking and nicotine dependence in first episode and established psychosis. Asian J Psychiatr. 2019; 43:125-131. DOI: 10.1016/j.ajp.2019.05.002. View

Pallares Vela E, Dave P, Cancarevic I . Clozapine-Related Thromboembolic Events. Cureus. 2021; 13(8):e16883. PMC: 8412001. DOI: 10.7759/cureus.16883. View

Sugino H, Futamura T, Mitsumoto Y, Maeda K, Marunaka Y . Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33(2):303-7. DOI: 10.1016/j.pnpbp.2008.12.006. View

Prestwood T, Asgariroozbehani R, Wu S, Agarwal S, Logan R, Ballon J . Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia. Behav Brain Res. 2021; 402:113101. PMC: 7882027. DOI: 10.1016/j.bbr.2020.113101. View

Monteiro R, Azevedo I . Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm. 2010; 2010. PMC: 2913796. DOI: 10.1155/2010/289645. View

Sagud M, Mihaljevic-Peles A, Muck-Seler D, Pivac N, Vuksan-Cusa B, Brataljenovic T . Smoking and schizophrenia. Psychiatr Danub. 2009; 21(3):371-5. View

10.

LaCapra S, Arkel Y, Ku D, Gibson D, Lake C, Lam X . The use of thrombus precursor protein, D-dimer, prothrombin fragment 1.2, and thrombin antithrombin in the exclusion of proximal deep vein thrombosis and pulmonary embolism. Blood Coagul Fibrinolysis. 2000; 11(4):371-7. DOI: 10.1097/00001721-200006000-00009. View

11.

Cheng Y, Liu Z, Yao F, Zeng W, Zheng D, Dong Y . Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis. PLoS Med. 2013; 10(9):e1001515. PMC: 3775725. DOI: 10.1371/journal.pmed.1001515. View

12.

Sadler J . Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998; 67:395-424. DOI: 10.1146/annurev.biochem.67.1.395. View

13.

Bresee L, Majumdar S, Patten S, Johnson J . Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res. 2010; 117(1):75-82. DOI: 10.1016/j.schres.2009.12.016. View

14.

Wilkowska A, Kujawska-Danecka H, Hajduk A . Risk and prophylaxis of venous thromboembolism in hospitalized psychiatric patients. A review. Psychiatr Pol. 2018; 52(3):421-435. DOI: 10.12740/PP/78891. View

15.

Cushman M . Epidemiology and risk factors for venous thrombosis. Semin Hematol. 2007; 44(2):62-9. PMC: 2020806. DOI: 10.1053/j.seminhematol.2007.02.004. View

16.

Chow V, Reddel C, Pennings G, Scott E, Pasqualon T, Ng A . Global hypercoagulability in patients with schizophrenia receiving long-term antipsychotic therapy. Schizophr Res. 2015; 162(1-3):175-82. DOI: 10.1016/j.schres.2014.12.042. View

17.

Mak Y, Loke A, Chiang V . Co-occurrence of schizophrenia and smoking: a qualitative study. Hong Kong Med J. 2019; 25 Suppl 2(1):21-27. View

18.

Dawson S, Henney A . The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis. 1992; 95(2-3):105-17. DOI: 10.1016/0021-9150(92)90014-8. View

19.

Kleijer B, Heerdink E, Egberts T, Jansen P, van Marum R . Antipsychotic drug use and the risk of venous thromboembolism in elderly patients. J Clin Psychopharmacol. 2010; 30(5):526-30. DOI: 10.1097/JCP.0b013e3181f0e87d. View

20.

Thorup M, Fog R . Clozapine treatment of schizophrenic patients. Plasma concentration and coagulation factors. Acta Psychiatr Scand. 1977; 55(2):123-6. DOI: 10.1111/j.1600-0447.1977.tb00148.x. View